Indegene

INDGN closed at ₹610.00 on 2026-11-06, trading in a narrow range following an extreme volume surge (+5.6% return, 5.51x volume ratio) on 2026-11-02. The daily technical structure is bullish, with price holding above all key moving averages and the Supertrend indicator. However, trend strength is weak (ADX 16.21), suggesting consolidation rather than aggressive momentum. This contrasts with a strong monthly trend (ADX 42.04) but a bearish monthly Supertrend, indicating a longer-term pullback within a broader uptrend. Price sits near the upper end of its 252-day range (+87.5%), approaching immediate resistance at ₹613.28 (0.54% away). A Doji formed on 2026-11-06 signals indecision after recent volatility. Upside requires a decisive break above ₹613.28 to confirm continuation; downside risk is supported by ₹604.53 (-0.90%).

On November 2, 2026, Motilal Oswal issued a 'Buy' recommendation for Indegene (INDGN), setting a price target of ₹718. This analyst note suggests potential upside for investors based on the brokerage's internal valuation models. As an external opinion, this rating reflects the firm's current assessment of the company's prospects but does not constitute a guarantee of future performance or a factual corporate announcement from Indegene itself.

Indegene (NSE: INDGN) has scheduled a one-on-one institutional investor meeting for November 13, 2026, in Bengaluru. The engagement with Mirabilis Investment Trust will focus on business updates and is confirmed to exclude unpublished price sensitive information. As of the observation date of November 6, 2026, the stock closed at ₹610.00, down from the previous close of ₹615.00.

Indegene Limited’s board approved unaudited financial results for the half-year ended September 30, 2026, reporting Q2 revenue of ₹11,223 million (US$117.5 million), a 39.5% year-on-year increase in INR terms. The company achieved an EBITDA of ₹1,873 million at a 16.7% margin and reported a profit after tax (PAT) of ₹1,123 million. Management maintained its outlook, targeting quarterly EBITDA margins of 19% or more by Q4 FY27. Governance changes include the resignation of director Mark Francis Dzialga effective October 29, 2026, and Company Secretary Srishti Ramesh Kaushik effective December 2, 2026. Additionally, the board allotted 52,194 shares under RSU and ESOP schemes. An institutional investor meeting with Mirabilis Investment Trust is scheduled for November 13, 2026, in Bengaluru.

Indegene’s operating trajectory has accelerated significantly, with TTM sales reaching ₹4,131 crore and a 36% compounded growth rate. The most recent quarter (Q1 FY2026-27) showed sequential revenue growth to ₹1,063.10 crore and a sharp rise in Profit Before Tax to ₹152.70 crore, driven by a substantial reduction in 'Other Unallocable Expenditure' from ₹59.90 crore to ₹20.70 crore. While operating profit expanded to ₹683 crore on a TTM basis, net profit remained flat at approximately ₹411 crore compared to the prior year, indicating that higher interest costs (₹25 crore TTM vs ₹19 crore last year) and depreciation are absorbing some of the operational gains.

Earnings quality remains robust, evidenced by strong cash conversion: CFO/EBITDA reached 129% in Mar 2026, and Cash from Operating Activity surged to ₹651 crore. However, balance-sheet leverage is rising; borrowings increased to ₹157 crore as of Sep 2026, coinciding with a decline in ROCE from 29% (Mar 2024) to 19% (Mar 2026). Fixed assets have grown substantially to ₹1,830 crore, suggesting ongoing capital deployment. Institutional ownership has shifted, with DIIs increasing their stake to 15.82% while total shareholders decreased to 132,280.

Indegene presents a conditional upside case anchored by improving short-term technical momentum and recent analyst validation, despite a bearish monthly trend. On the daily timeframe, the stock closed at ₹610 on November 6, 2026, with the Supertrend indicator signaling a bullish direction. This short-term strength is supported by positive slope readings for both the 20-day EMA (9.02) and SMA (4.56), alongside a Plus DI (23.95) significantly higher than the Minus DI (17.41), suggesting buying pressure has outweighed selling pressure in the near term. The weekly chart reinforces this constructive view, also showing a bullish Supertrend and strong positive slopes for moving averages. Furthermore, Motilal Oswal issued a 'Buy' recommendation with a price target of ₹718, providing an external benchmark for potential appreciation from current levels. However, investors should note that the monthly trend remains bearish, indicating that the broader medium-term trajectory has not yet confirmed a sustained reversal.

As of 6 November 2026, Indegene (NSE: INDGN) presents a mixed technical setup that warrants caution despite short-term bullish signals. The stock closed at ₹610.00, down from the previous close of ₹613.35, with a market capitalization of approximately ₹14,780 crore. While the daily and weekly trends show bullish momentum—indicated by Supertrend directions and positive slope metrics—the monthly trend is bearish, suggesting underlying medium-term weakness. The stock is currently trading just below immediate resistance levels, specifically the high of ₹613.28 (0.54% above current price) and the pivot at ₹620.37 (1.70% above). A failure to break these near-term hurdles could expose the stock to downside support levels at ₹604.53 and ₹595.72. Furthermore, volatility remains elevated, with an annualized volatility of +32.8% and an Average True Range (ATR) of 3.34%, indicating significant price fluctuation risk. The stock has experienced a maximum drawdown of -37.1% historically, though the current drawdown stands at -9.5%. Investors should monitor the ability to sustain prices above the ₹600 psychological level and the ₹613 resistance zone for confirmation of trend stability.